|
14 March 2005 – Cambridge
imaging pioneer TeraView has revealed its plans to
expand into the US as it seeks to push into the biggest
pharmaceutical market in the world. Probably best known for its technology
for screening for plastic explosives and concealed
weapons, the company has launched a revolutionary
imaging machine aimed at the pharmaceutical industry,
which it unveiled at a key US trade show recently. The technology has a number of
key applications within the industry, including checking
that drug molecules do not change their structure
as part of the manufacturing process, as well as
checking for cracks in tablets. TeraView Ltd is the world’s
first company solely devoted to the commercial exploitation
of Terahertz light. Terahertz light lies between
microwave and infrared and represents the last unexplored
region of the radio wave and light spectrum. It has applications in screening
and imaging in a number of markets.
Chief executive, Don Arnone
said TeraView planned to establish a sales and
marketing operation in New Jersey in the near future,
with a technical function bolted on as demand requires.
He said: "75 per cent of
the pharma companies in the US are based between
Boston and Washington DC, so New Jersey represents
a strategically sound base for our operations. "The
total addressable market is valued at around £500m
and we plan to have penetrated about 10 per cent
of it within the next three to four years."
The technology is being evaluated
by US drug regulator, the FDA, with the possibility
that the technology will be integrated into its own
processes, in addition to a number of leading companies. 
|
